United States of America

FDA Approves Rasonque for Pancreatic Cancer

Is this a lifeline for pancreatic cancer patients or a gateway to conquering the "undruggable" KRAS mutation across all cancers?

10 hours ago·Updated 6 hours ago

FDA Approves Rasonque for Pancreatic Cancer

Story

Above: Daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in development by Revolution Medicines, on July 24. Image credit: Nikos Frazier/Omaha World-Herald/Getty Images

The Spin

Narrative A

This is a critical breakthrough for one of medicine's most brutal diseases. Daraxonrasib nearly doubled median survival in patients who had already failed chemotherapy, and some lived for years. For a cancer with a five-year survival rate of just 13%, that kind of result is extraordinary.

Jorge Conde on X Scientific American

Narrative B

Rasonque's approval matters beyond just pancreatic cancer — KRAS inhibition cracks open a target that defined "undruggable" for four decades, affecting roughly 20% of all cancers worldwide. First-line combination studies are already posting response rates near 60%, and the same mechanism could eventually reach colorectal, lung and even rare childhood cancers. This is the beginning of an entirely new class of treatments.

Anirban Maitra on X Economist

Afshine Emrani MD FACC on X

Establishment-critical narrative

Today's FDA approval is a major new option, but not a cure. Rasonque nearly doubled median survival in previously treated metastatic pancreatic cancer, however, patients still progressed, and resistance emerged in 59% of those studied for its mechanisms. The next combinations remain largely preclinical, so the real test is whether this survival gain can become durable.

Nature